Literature DB >> 16444588

Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production.

Yelena A Shmist1, Igor Goncharov, Maor Eichler, Vladimir Shneyvays, Ahuva Isaac, Zvi Vogel, Asher Shainberg.   

Abstract

Delta-9-tetrahydrocannabinol (THC), the major active component of marijuana, has a beneficial effect on the cardiovascular system during stress conditions, but the defence mechanism is still unclear. The present study was designed to investigate the central (CB1) and the peripheral (CB2) cannabinoid receptor expression in neonatal cardiomyoctes and possible function in the cardioprotection of THC from hypoxia. Pre-treatment of cardiomyocytes that were grown in vitro with 0.1 - 10 microM THC for 24 h prevented hypoxia-induced lactate dehydrogenase (LDH) leakage and preserved the morphological distribution of alpha-sarcomeric actin. The antagonist for the CB2 (10 microM), but not CB1 receptor antagonist (10 microM) abolished the protective effect of THC. In agreement with these results using RT-PCR, it was shown that neonatal cardiac cells express CB2, but not CB1 receptors. Involvement of NO in the signal transduction pathway activated by THC through CB2 was examined. It was found that THC induces nitric oxide (NO) production by induction of NO synthase (iNOS) via CB2 receptors. L-NAME (NOS inhibitor, 100 microM) prevented the cardioprotection provided by THC. Taken together, our findings suggest that THC protects cardiac cells against hypoxia via CB2 receptor activation by induction of NO production. An NO mechanism occurs also in the classical pre-conditioning process; therefore, THC probably pre-trains the cardiomyocytes to hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16444588     DOI: 10.1007/s11010-006-2346-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

Review 1.  Nitric oxide and the other cyclic nucleotide.

Authors:  Claudette Klein
Journal:  Cell Signal       Date:  2002-06       Impact factor: 4.315

Review 2.  Medical efficacy of cannabinoids and marijuana: a comprehensive review of the literature.

Authors:  Sean M Bagshaw; Neil A Hagen
Journal:  J Palliat Care       Date:  2002       Impact factor: 2.250

3.  Expression of a brain-type cannabinoid receptor (CB1) in alveolar Type II cells in the lung: regulation by hydrocortisone.

Authors:  W Rice; J M Shannon; F Burton; D Fiedeldey
Journal:  Eur J Pharmacol       Date:  1997-05-30       Impact factor: 4.432

Review 4.  Cardiovascular consequences of marijuana use.

Authors:  Stephen Sidney
Journal:  J Clin Pharmacol       Date:  2002-11       Impact factor: 3.126

Review 5.  Cardiovascular system effects of marijuana.

Authors:  Reese T Jones
Journal:  J Clin Pharmacol       Date:  2002-11       Impact factor: 3.126

6.  Marijuana smoke and Delta(9)-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis.

Authors:  T A Sarafian; D P Tashkin; M D Roth
Journal:  Toxicol Appl Pharmacol       Date:  2001-08-01       Impact factor: 4.219

Review 7.  Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research.

Authors:  R Bolli
Journal:  J Mol Cell Cardiol       Date:  2001-11       Impact factor: 5.000

8.  Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Authors:  A R Schatz; M Lee; R B Condie; J T Pulaski; N E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  1997-02       Impact factor: 4.219

9.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

10.  Comparative trial of the antiemetic effects of THC and haloperidol.

Authors:  J A Neidhart; M M Gagen; H E Wilson; D C Young
Journal:  J Clin Pharmacol       Date:  1981 Aug-Sep       Impact factor: 3.126

View more
  15 in total

Review 1.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

3.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

4.  CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; György Haskó; Lucas Liaudet; John W Huffman; Anna Csiszar; Zoltan Ungvari; Ken Mackie; Subroto Chatterjee; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-27       Impact factor: 4.733

5.  Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies.

Authors:  Sabine Steffens; Pál Pacher
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

6.  Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase.

Authors:  Sándor Bátkai; Mohanraj Rajesh; Partha Mukhopadhyay; György Haskó; Lucas Liaudet; Benjamin F Cravatt; Anna Csiszár; Zoltan Ungvári; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-13       Impact factor: 4.733

7.  CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

Authors:  M Rajesh; P Mukhopadhyay; G Haskó; J W Huffman; K Mackie; P Pacher
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 8.  Endocannabinoids and the heart.

Authors:  C Robin Hiley
Journal:  J Cardiovasc Pharmacol       Date:  2009-04       Impact factor: 3.105

9.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

10.  Bioisosteric replacement of central 1,2,4-oxadiazole ring of high affinity CB2 ligands by regioisomeric 1,3,4-oxadiazole ring.

Authors:  Dominik Heimann; Corinna Lueg; Henk de Vries; Bastian Frehland; Dirk Schepmann; Laura H Heitman; Bernhard Wünsch
Journal:  Medchemcomm       Date:  2017-07-19       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.